Skip to main content
. Author manuscript; available in PMC: 2019 Feb 6.
Published in final edited form as: Curr Alzheimer Res. 2014;11(7):655–663. doi: 10.2174/1567205011666140812114037

Fig. (2). Six months IVIG reduces the number of NFT-bearing CA1 neurons.

Fig. (2).

A-D) Photomicrographs show AT-180 immunolabeling of CA1 pyramidal neurons and fibers in 3xTg mice treated with placebo (A,C) or IVIG (B,D) for six months. Panels (C) and (D) are higher magnification photomicrographs of (A) and (B), respectively. E) Unbiased stereologic cell counts revealed a significant 25–30% reduction in the number of AT-180+ neurons in IVIG compared to placebo-treated mice. F) Optical densitometric measurements revealed no differences in AT-180 labeling intensity between the two groups. n = 11–13/group; *, p< 0.01 via Student’s unpaired t test (two-tailed).